CGC Stock Analysis: Buy, Sell, or Hold?
CGC - Canopy Growth Corporation Common Shares
$0.88
-0.01 (-0.79%)
▼
5d:
-7.02%
30d:
-9.58%
90d:
-8.81%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 06, 2026
Get Alerted When CGC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CGC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CGC shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CGC is currently trading at $0.88, which is considered oversold relative to its 30-day fair value range of $0.91 to $1.00. From a valuation perspective, the stock is trading at a discount (Forward PE: -3.4) compared to its historical average (13.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CGC is in a downtrend. The price is currently testing key support at $0.86. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CGC scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.20 (+36.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CGC is in a downtrend. The price is currently testing key support at $0.86. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CGC scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.20 (+36.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.91 -
$1.00
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
61.9%
Protect Your Profits
Holding CGC? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 36.5% below Wall St target ($1.20)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 35/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.91 -
$1.00
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.86
Resistance Level
$0.98
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.42
Wall Street Target
$1.20
(+36.5%)
Revenue Growth (YoY)
12.5%
Profit Margin
-79.2%
PE vs Historical
-3.4 vs 13.0
CHEAP
Share & Embed Analysis
Last updated: October 03, 2026 3:34 AM ET
Data refreshes hourly during market hours. Next update: 4:34 AM
Data refreshes hourly during market hours. Next update: 4:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
Advanced CGC Option Strategies
Professional options setups generated by AI based on today's CGC price and gamma walls.
